Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19 May 3, 2021
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 Mar 24, 2021
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion… Feb 26, 2021
Mountain Valley MD To Include Testing Of South African Mutation In Upcoming COVID-19 BSL-4 Clearance Work Feb 22, 2021